Whitehawk Therapeutics (WHWK) Income from Continuing Operations (2010 - 2026)
Whitehawk Therapeutics (WHWK) reported Income from Continuing Operations of 22194000.0 for Q1 2026, down 130.4% year-over-year from 73016000.0 in Q1 2025, and down 125.57% quarter-over-quarter from 86799000.0 in Q4 2025.
Whitehawk Therapeutics (WHWK) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Whitehawk Therapeutics (WHWK) has 17 years of Income from Continuing Operations data on file, last reported at 22194000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 22194000.0, down 130.4% year-over-year; the trailing twelve-month figure through Mar 2026 was 5861000.0 (down 121.22% YoY), and the FY2025 annual result was 20596000.0, up 67.66% from the prior year.
- Income from Continuing Operations declined to 22194000.0 in Q1 2026 per WHWK's latest filing, from 86799000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 86799000.0 in Q4 2025 and troughed at 52770000.0 in Q2 2025.
- A 5-year average of 7224117.65 and a median of 16269000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations slumped 1089.39% in 2022, then soared 575.01% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 13913000.0 in 2022, then decreased by 16.93% to 16269000.0 in 2023, then retreated by 12.32% to 18273000.0 in 2024, then soared by 575.01% to 86799000.0 in 2025, then sank by 125.57% to 22194000.0 in 2026.
- Business Quant data shows WHWK's Income from Continuing Operations at 22194000.0 in Q1 2026, 86799000.0 in Q4 2025, and 17696000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Whitehawk Therapeutics | 310.18 Mn | 187.14 Mn | - | -22.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.19 Mn |
| Dec 31, 2025 | 86.80 Mn |
| Sep 30, 2025 | -17.70 Mn |
| Jun 30, 2025 | -52.77 Mn |
| Mar 31, 2025 | 73.02 Mn |
| Dec 31, 2024 | -18.27 Mn |
| Sep 30, 2024 | -12.55 Mn |
| Jun 30, 2024 | -14.58 Mn |
| Mar 31, 2024 | -18.29 Mn |
| Dec 31, 2023 | -16.27 Mn |
| Sep 30, 2023 | -16.30 Mn |
| Jun 30, 2023 | -17.97 Mn |
| Mar 31, 2023 | -15.22 Mn |
| Dec 31, 2022 | -13.91 Mn |
| Sep 30, 2022 | -14.47 Mn |
| Jun 30, 2022 | -18.27 Mn |
| Mar 31, 2022 | -13.86 Mn |
| Dec 31, 2021 | -15.99 Mn |
| Sep 30, 2021 | -87.09 Mn |
| Jun 30, 2021 | -1.54 Mn |